



# CONSENSUS CONFERENCE 2019

ROTTERDAM | NETHERLANDS

FEBRUARY 7, 2019



INTERNATIONAL LIVER  
TRANSPLANTATION SOCIETY

[www.ilts.org](http://www.ilts.org)

## PROGRAM



## TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT

### Program Chairs

#### **Nancy Kwan Man, MBBS, PhD**

*Director, Clinical and Translational Research Laboratory*

*Director, Laboratory for Liver Transplantation and Liver Cancer*

*Deputy Director, Laboratory for Organ Transplantation and Regeneration*

*Professor, Department of Surgery*

*The University of Hong Kong*

#### **R. Mark Ghobrial, M.D., Ph.D., FACS, FRCS (Ed)**

*Sherrie and Alan Conover Endowed Chair*

*Director, Sherrie & Alan Conover Center for Liver Disease & Transplantation*

*Chief, Liver Transplantation Surgery*

*Director, Immunobiology Research Center*

*Professor of Surgery*

*Weill Cornell Medical College*

#### **Taizo Hibi, MD, PhD, FACS**

*Professor and Chairman*

*Department of Pediatric Surgery and Transplantation*

*Kumamoto University Graduate School of Medical Sciences*

*Director, Organ Transplant Center*

*Kumamoto University Hospital*

#### **Gonzalo Sapisochin, MD, PhD, MSc**

*Assistant Professor of Surgery*

*Abdominal Transplant and HPB Surgical Oncology*

*University Health Network*

*University of Toronto*

### Brief Introduction

Transplant oncology is a new concept encompassing multiple disciplines of transplantation medicine and oncology to take hepatobiliary cancer treatment and research to the next level. The Consensus Conference in Rotterdam will convene worldwide experts and opinion leaders in transplant surgery, radiology and oncology, hepatology and immunology to discuss the frontiers and future perspectives of multidisciplinary management of hepatobiliary malignancies.

The main topics will include liver transplantation for hepatocellular carcinoma, cholangiocarcinoma, colorectal and neuroendocrine liver metastases, pediatric malignancy, therapies for cancer recurrence after liver transplantation and role of novel chemotherapeutic and biological agents to enhance transplantation outcomes.

### Learning objectives

1. Understand the gap between the current practice and the future of transplant oncology
2. Update selection criteria, prediction models and emerging indications
3. Identify novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches



## TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT

- 08:00      **Welcome Remark**  
Wojciech Polak, MD, PhD Erasmus MC – Rotterdam, The Netherlands
- 
- 08:05 – 09:20      **Introductory Lectures**  
Chairs:  
Nancy Kwan Man, MBBS, PhD The University of Hong Kong – Hong Kong, China  
Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada  
Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy
- 08:05 – 08:20      **Transplant oncology – Current perspectives**  
John Roberts, MD University of California San Francisco – San Francisco, CA, USA
- 08:20 – 08:50      **The future of transplant oncology: Bridging the gap**  
Vincenzo Mazzaferro, MD Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy  
Bruno Sangro, MD, PhD The University of Navarra School of Medicine – Pamplona, Spain
- 08:50 – 09:20      **Novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches**  
R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA  
Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA
- 
- 09:30 – 13:00      **Consensus Conference Lectures**  
**PART I**  
Chairs:  
Vincenzo Mazzaferro, MD Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy  
Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences – Kumamoto, Japan  
Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA
- 09:30 – 10:00      **The update of liver transplantation for HCC**  
**Western experience**  
Francis Yao, MD University of California: San Francisco – San Francisco, CA, USA  
**Eastern experience**  
Avi Soin, MD Medanta – The Medicity, India
- 10:00 – 10:30      **The update of liver transplantation for CCA**  
Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA  
Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada



## TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT

10:30 – 10:45 Coffee Break

### **PART II**

Chairs:

R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA

Wojciech Polak, MD, PhD Erasmus MC – Rotterdam, The Netherlands

John Fung, MD, PhD University of Chicago Medicine Transplant Institute – Chicago, IL, USA

10:45 – 11:15

### **Emerging indications for liver transplantation: colorectal and neuroendocrine liver metastases**

James Eason, MD Methodist University Transplant – Memphis, TN, USA

Pal Dag Line, MD, PhD Oslo University Hospital – Oslo, Norway

11:15 – 11:45

### **Pediatric transplant oncology**

Mohamed Rela, MD Gleneagles Global Hospital – Chennai, India

Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences – Kumamoto, Japan

11:45 – 12:00

Coffee Break

### **PART III**

Chairs:

Jan Lerut, MD, PhD University Hospitals Saint Luc – Brussels, Belgium

Valeria Mas, M.S., PhD, FAST Methodist University Hospital – Memphis, TN, USA

Yaman Tokat, MD Florence Nightingale Hospital – Istanbul, Turkey

12:00 – 12:30

### **Post-transplant management for cancer recurrence**

Sherrie Bhoori, MD National Cancer Institute – Milan, Italy

Shusen Zheng, MD, PhD Zhejiang University – Hangzhou, China

12:30 – 13:00

### **The changes of transplant indications**

**DAA therapies**

Marina Berenguer, MD Hospital La Fe – Valencia, Spain

**NASH/HCC**

Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy

13:00 – 14:00

Lunch Break

14:00 – 15:30

### **Working Group Discussions**



# TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT

## 1. Liver transplantation for HCC

- Updates on the selection criteria
- Prediction models
- Downstaging and bridging therapies
- Should small tumors be treated by ablation and reserve OLT for large cancers?

Group leaders:

Vincenzo Mazzaferro, MD Fondazione IRCCS Istituto Nazionale dei Tumori di Milano – Milan, Italy

Neil Mehta, PhD University of California: San Francisco – San Francisco, CA, USA

Avi Soin, MD Medanta – The Medicity, India

Working Group members:

Shusen Zheng, MD, PhD Zhejiang University – Hangzhou, China

Jan Ijzermans, MD, PhD Erasmus MC – Rotterdam, The Netherlands

John Roberts, MD University of California San Francisco – San Francisco, CA, USA

François Durand, MD Hospital Beaujon – Clichy, France

Nobuhisa Akamatsu, MD, PhD The University of Tokyo – Tokyo, Japan

Francis Yao, MD University of California San Francisco – San Francisco, CA, USA

Wojciech Polak, MD, PhD Erasmus MC – Rotterdam, The Netherlands

Prashant Bhangui, MBBS, MS Medanta Institute of Liver Transplantation and Regenerative Medicine – Gurgaon, India

## 2. Liver transplantation for CCA /mixed HCC/CCA

- Hilar CCA
- Intrahepatic CCA
- Mixed HCC/CCA (Outcomes, diagnostic and prognostic tools, adjuvant treatments)

Group Leaders:

Julie Heimbach, MD Mayo Clinic Rochester – Rochester, ME, USA

Gonzalo Sapisochin, MD Toronto General Hospital – Toronto, Canada

Milind Javle, MD University of Texas MD Anderson Cancer Center – Houston, TX, USA

Working Group Members:

R. Mark Ghobrial MD, PhD, FRCS Methodist Hospital – Houston, TX, USA

Masayuki Ohtsuka, MD, PhD Chiba University – Chiba, Japan

Darwish-Murad Sarwa, MD Erasmus MC – Rotterdam, The Netherlands

Daniel Maluf, MD Methodist University Hospital – Memphis, TN, USA

Gabriela Berlakovich, MD Medical University of Vienna – Vienna, Austria

Jan Lerut, MD, PhD University Hospitals Saint Luc Catholic of the University of Louvain – Louvain, Belgium





## TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT

### 3. Less common tumors of transplant oncology

- a. Colorectal liver metastasis
- b. Neuroendocrine liver metastasis
- c. Tumors in the pediatric population and other rare tumor

Group Leaders:

Mohamed Rela, MD Gleneagles Global Hospital – Chennai, India

Taizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences Kumamoto, Japan

James Eason, MD Methodist University Transplant – Memphis, TN, USA

Group Members:

Pal Dag Line, MD, PhD Oslo University Hospital – Oslo, Norway

John Fung, MD, PhD University of Chicago Medicine Transplant Institute – Chicago, IL, USA

Seisuke Sakamoto, MD, PhD National Center for Child Health and Development – Tokyo, Japan

Nazia Selzner, MD, PHD University of Toronto – Toronto, Canada

### 4. Post-transplant management

- a. Tailored immunosuppression for cancer recipients
- b. Cancer recurrence prediction models and surveillance strategies
- c. New adjuvant therapies for recurrence after OLT  
(chemotherapy, immunotherapy, new biological treatment and radiotherapy)

Group Leaders:

Marina Berenguer, MD Hospital La Fe – Valencia, Spain

Patrizia Burra, MD, PhD Padova University Hospital – Padova, Italy

Herold Metselaar, MD, PhD Erasmus MC – Rotterdam, The Netherlands

Group members:

Nancy Kwan Man, MBBS, PhD The University of Hong Kong – Hong Kong, China

Sherrie Bhoori, MD National Cancer Institute – Milan, Italy

Valeria Mas, M.S., PhD, FAST Methodist University Hospital – Memphis, TN, USA

Bruno Sangro, MD, PhD The University of Navarra School of Medicine, Pamplona, Spain

Masahiro Ohira, PhD Hiroshima University Hospital – Higashihiroshima, Japan

Luc van der Laan, PhD Erasmus MC – Rotterdam, The Netherlands

---

15:30 – 16:00	Coffee Break
16:00 – 18:00	<b>Working Group Presentations with Statements</b>
18:00 – 18:30	<b>Summary</b>



## TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT



**EACCME**  
European Accreditation Council  
for Continuing Medical Education

### CONTINUING MEDICAL EDUCATION (CME) CREDITS

**The ILTS 2019 Consensus Conference: Transplant Oncology - The Future of Multidisciplinary Management, Rotterdam, Netherlands, 07/02/2019-07/02/2019** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



ILTS 2019 Consensus Conference: Transplant Oncology – the Future of Multidisciplinary Management is now compliant with the MedTech Europe Code of Ethical Business Practice [www.ethicalmedtech.eu](http://www.ethicalmedtech.eu).



## TRANSPLANT ONCOLOGY THE FUTURE OF MULTIDISCIPLINARY MANAGEMENT

### ILTS Headquarters

ILTS Headquarters  
K.I.T. Group GmbH  
Association & Conference Management  
Kurfürstendamm 71  
10709 Berlin  
Germany  
Phone: +49 (0) 30 24603 349  
Fax: +49 (0) 30 24603 200  
ilts@ilts.org  
[www.ilts.org](http://www.ilts.org)

### Conference Venue

Hilton Rotterdam  
Weena 10  
3012 CM Rotterdam  
Netherlands

### Session Rooms

Le Jardin, Maaskant, Coolsingel Suite, Kruiskade, Conrad Suite

### Registration

Please register [here](#) by February 6, 2019,  
23:59 CET (GMT+2)

Should you require further assistance please don't hesitate to  
contact the ILTS Registration Department:  
[ilts-consensusregistration@kit-group.org](mailto:ilts-consensusregistration@kit-group.org)  
Hotline: +49 30 24603 410

### Accommodation at Conference Venue Hotel

All participants are responsible for their own accommodation.  
The Conference organizers have reserved a limited contingent of  
rooms in advance for attendees at the venue hotel. Please contact  
the hotel and let them know that you wish to book a room out of  
the contingent.

To book a room please click [here](#)